Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - Principia Biopharma Inc. | d636249dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 16, 2018
PRINCIPIA BIOPHARMA INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-38653 | 26-3487603 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||
400 East Jamie Court, Suite 302 South San Francisco, California |
94080 | |||
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code: (650) 416-7700
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
❑ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
❑ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
❑ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
❑ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b2 of the Securities Exchange Act of 1934 (§ 240.12b2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. | Other Events. |
On October 16, 2018, Principia Biopharma Inc. (the Company) issued a press release announcing the achievement of clinical development milestones related to its proprietary drug candidate, PRN2246, also known as SAR442168. As a result, pursuant to the License Agreement by and between the Company and Genzyme Corporation (Sanofi) dated as of November 8, 2017, as amended on May 24, 2018, Sanofi is obligated to make $10.0 million in milestone payments to the Company.
A copy of this press release is attached as Exhibit 99.1 hereto.
Item 9.01 | Financial Statements and Exhibits. |
(d) | Exhibits |
Exhibit No. |
Description | |
99.1 | Press Release issued by Principia Biopharma Inc. dated October 16, 2018. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PRINCIPIA BIOPHARMA INC. | ||
By: | /s/ Christopher Y. Chai | |
Christopher Y. Chai Chief Financial Officer |
Dated: October 18, 2018